Suppr超能文献

钾通道开放剂对用钾停搏液处理的缺血大鼠心脏的保护作用。

Protective effect of K(ATP) openers in ischemic rat hearts treated with a potassium cardioplegic solution.

作者信息

Grover G J, Sleph P G

机构信息

Department of Pharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey, USA.

出版信息

J Cardiovasc Pharmacol. 1995 Nov;26(5):698-706. doi: 10.1097/00005344-199511000-00005.

Abstract

ATP-sensitive potassium channel (KATP) openers directly protect ischemic myocardium, which may make them useful for treating patients undergoing cardiopulmonary bypass, but whether high-potassium-containing cardioplegic solutions would inhibit their protective effects is not clear. We determined whether additional protection greater than that provided by cardioplegia could be found for KATP openers. We studied the effect of 10 microM cromakalim or BMS-180448 pretreatment (10 min before cardioplegia) on severity of ischemia in isolated rat hearts given normothermic or cold St. Thomas' cardioplegic solution (16 mM K+). After cardioplegic arrest, the hearts were subjected to 30-min (normothermic) or 150-min (hypothermic) global ischemia, each followed by 30-min reperfusion. The cardioplegic solutions significantly protected the hearts, as measured by increased time to onset of contracture, enhanced recovery of function, and reduced lactate dehydrogenase (LDH) release. Cromakalim and BMS-180448 both further significantly increased time to contracture in both normothermic and hypothermic arrested hearts; this was accompanied by enhanced recovery of reperfusion contractile function and reduced cumulative LDH release. This additional protective effect of the K ATP openers was abolished by glyburide. Because administration of the K ATP openers only with the cardioplegic solution (1 min before global ischemia) was not efficacious, >1-min pretreatment apparently is necessary. K ATP openers provide additional protection to that afforded by cold or normothermic potassium cardioplegia in rat heart, although the timing of treatment may be crucial.

摘要

ATP敏感性钾通道(KATP)开放剂可直接保护缺血心肌,这可能使其对接受体外循环的患者治疗有用,但含高钾的心脏停搏液是否会抑制其保护作用尚不清楚。我们确定是否能发现KATP开放剂具有比心脏停搏液提供的保护作用更大的额外保护作用。我们研究了10微摩尔克罗卡林或BMS-180448预处理(心脏停搏前10分钟)对给予常温或冷St. Thomas心脏停搏液(16毫摩尔钾离子)的离体大鼠心脏缺血严重程度的影响。心脏停搏后,心脏经历30分钟(常温)或150分钟(低温)的全心缺血,随后各进行30分钟的再灌注。通过挛缩开始时间增加、功能恢复增强和乳酸脱氢酶(LDH)释放减少来衡量,心脏停搏液显著保护了心脏。克罗卡林和BMS-180448在常温及低温停搏心脏中均进一步显著增加了挛缩时间;这伴随着再灌注收缩功能恢复增强和LDH累积释放减少。格列本脲消除了KATP开放剂的这种额外保护作用。由于仅在心脏停搏液给药时(全心缺血前1分钟)给予KATP开放剂无效,因此显然需要>1分钟的预处理。KATP开放剂在大鼠心脏中对冷或常温钾心脏停搏液提供的保护作用具有额外的保护作用,尽管治疗时机可能至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验